KCNJ11 and glioma: To this aim, AQP4-OAPs or AQP4-tetramers expressing glioma cells were treated with zoledronic acid, a Kir6.2-SUR2 K ATP channel inhibitor [45,59], and with KATP channel agonist diazoxide.